Skip to Content

Synergy Pharmaceuticals Inc.

Company NameSynergy Pharmaceuticals Inc.
Stock SymbolSGYP
Class PeriodNovember 10, 2016 to November 13, 2017
Lead Plaintiff Motion DeadlineApril 10, 2018

On September 5, 2017, Synergy revealed that it had closed on a "non-dilutive" $300 million loan from CRG Partners III L.P., which would be available to the Company "when needed" to fund its operations through 2019. On November 14, 2017, Synergy revealed the loan agreement terms, that was not previously disclosed, prevented the Company from accessing $200 million of the loan without conducting a dilutive secondary offering or offerings of shares to raise cash, and therefore, Synergy was conducting a secondary offering of its shares.  Consequently, the loan was not available to Synergy "when needed," and would result in dilution of the outstanding shares, and would not be sufficient to fund operations through 2019, without dilution.  On this news, shares of Synergy fell significantly, thereby injuring investors.

Submit Your Information

If you suffered a loss on your Synergy Pharmaceuticals Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.

An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.

Shares Purchased

Number of SharesBuy DatePrice Per ShareAdd

Shares Sold

Number of SharesSell DatePrice Per ShareAdd